Investor Relations

Press Releases

  • DATE
  • TITLE AND SUMMARY
  • VIEW
May 23, 2019

TEL AVIV, Israel , May 23, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today announced the upcoming presentation of final results from the Phase 2 study of VB-111 in ovarian cancer at the American Society of Clinical Oncology ( ASCO ) 2019 Annual Meeting, to be held May 31 - June 4,...

May 15, 2019

Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel , May 15, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the first quarter ended March 31, 2019 , and provided a corporate update. “As we continue to advance development of...

May 06, 2019

TEL AVIV, Israel , May 06, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast...

March 28, 2019

Development of Phase 3 product candidate VB-111 continues in ovarian cancer toward interim analysis at year-end 2019 and expands through investigator-sponsored trials in rGBM and colon cancer Signed strategic agreement for VB-201 for veterinary use; potential payments to VBL may exceed €50 million...

March 25, 2019

TEL AVIV, Israel , March 25, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today announces that the Company will present data on its Phase 3 drug candidate VB-111, at the 2019 American Association for Cancer Research (AACR) Annual Meeting , to be held March 29 - April 3, 2019 at...

March 19, 2019

Data Presented at Society of Gynecologic Oncology (SGO) 50th Annual Meeting on Women's Cancer® TEL AVIV, Israel , March 19, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today announced the presentation of human data indicating that the viral anti-cancer investigational therapy VB-111...

March 14, 2019

TEL AVIV, Israel , March 14, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio...

March 11, 2019

TEL AVIV, Israel , March 11, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that the company will present data on its Phase 3...

February 26, 2019

TEL AVIV, Israel, Feb. 26, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), (the “Company”) today announced new data implicating the potential of its VB-600 platform of antibodies targeting MOSPD2 (motile sperm domain-containing protein 2) for treatment of various inflammatory...

February 20, 2019

TEL AVIV, Israel , Feb. 20, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (the “Company”) today announced that it has been awarded a non-dilutive grant of over 10 million New Israeli Shekels (approximately $2.9 million ) by the Israel Innovation Authority (IIA) for 2019.  The funds will...

View all press releases »